Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multiple drug-resistant tuberculosis

W Z Bradford1, C L Daley

  • 1Division of Infectious Diseases, San Francisco General Hospital, California, USA.

Infectious Disease Clinics of North America
|March 12, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of the novel nontuberculous mycobacterial pulmonary disease symptoms scale (NTM-SS).

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

Michael Dee Iseman, MD - the passing of a legend.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2023
Same author

International Society of Cardiovascular Infectious Diseases Guidelines for the Diagnosis, Treatment and Prevention of Disseminated Mycobacterium chimaera Infection Following Cardiac Surgery with Cardiopulmonary Bypass.

The Journal of hospital infection·2019
Same author

The epidemiologic relationship between tuberculosis and non-tuberculous mycobacterial disease: a systematic review.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2014
Same author

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update.

The European respiratory journal·2011
Same author

Pulmonary non-tuberculous mycobacterial infections.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2010

Drug-resistant tuberculosis, including multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, poses significant challenges to public health. Effective management requires careful treatment selection and adherence to prevent adverse outcomes.

Area of Science:

  • Public Health
  • Infectious Diseases
  • Microbiology

Background:

  • The rise of drug-resistant Mycobacterium tuberculosis strains complicates tuberculosis (TB) control and patient treatment.
  • Multidrug-resistant (MDR) TB in the U.S. is regionalized, influenced by factors like the HIV epidemic.
  • Drug-resistant TB, including extensively drug-resistant (XDR) and multidrug-resistant (MDR) forms, arises from control program deficiencies.

Purpose of the Study:

  • To outline the complexities and management principles for drug-resistant tuberculosis.
  • To highlight the challenges posed by MDR, PDR, and ADR tuberculosis strains.
  • To emphasize critical considerations for treating drug-resistant TB cases.

Main Methods:

  • Review of current understanding of drug-resistant tuberculosis epidemiology and clinical management.

Related Experiment Videos

  • Analysis of treatment principles for MDR tuberculosis.
  • Discussion of factors influencing regimen selection and therapy duration.

    • Main Results:

    • Drug-resistant TB necessitates specialized clinical management and often leads to poor outcomes.
    • Key management strategies include using multiple susceptible agents and avoiding monotherapy addition.
    • Patient adherence is crucial for successful treatment of drug-resistant TB.

    Conclusions:

    • Managing drug-resistant TB is complex, requiring expert consultation and adherence to specific therapeutic principles.
    • Treatment regimens must be tailored to resistance patterns, drug toxicities, and patient response.
    • Preventive therapy for contacts of MDR TB cases warrants consideration, despite limited supporting evidence.